Logo

AIMD

Ainos, Inc.

AIMD

Ainos, Inc. • NASDAQ
$2.08 ▼ -1.42% (-0.03)
Market Cap $10.01 M
52w High $5.00
52w Low $1.78
Dividend Yield 0%
P/E -0.53
Volume 10.97K
Outstanding Shares 4.81M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $2.167K ▼ $2.786M ▼ $-2.932M ▲ -135.289K% ▼ $-0.64 ▲ $-1.548M ▲
Q2-2025 $4.663K ▼ $3.749M ▲ $-4.085M ▼ -87.604K% ▼ $-0.99 ▲ $-2.713M ▼
Q1-2025 $106.207K ▲ $3.251M ▼ $-3.286M ▲ -3.094K% ▼ $-207.15 ▼ $-1.928M ▲
Q4-2024 $0 $4.634M ▲ $-4.654M ▼ 0% $-0.49 ▼ $-3.278M ▼
Q3-2024 $0 $3.038M $-3.699M 0% $-0.33 $-2.223M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $1.128M ▼ $22.679M ▼ $12.634M ▲ $10.045M ▼
Q2-2025 $1.223M ▼ $23.922M ▼ $12.479M ▼ $11.443M ▼
Q1-2025 $2.628M ▼ $26.353M ▼ $13.231M ▼ $13.122M ▼
Q4-2024 $3.893M ▼ $28.82M ▼ $13.304M ▼ $15.516M ▼
Q3-2024 $5.157M $31.37M $13.348M $18.022M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-2.932M ▲ $-1.185M ▲ $4.933K ▲ $1.134M ▲ $-94.967K ▲ $-1.195M ▲
Q2-2025 $-4.085M ▼ $-1.35M ▼ $2.542K ▲ $-295.507K ▼ $-1.405M ▼ $-1.343M ▼
Q1-2025 $-3.286M ▲ $-1.225M ▼ $-20.587K ▼ $14.605K ▲ $-1.265M ▼ $-1.258M ▼
Q4-2024 $-4.654M ▼ $-864.231K ▲ $13.285K ▲ $-270K ▲ $-1.264M ▲ $-865.139K ▲
Q3-2024 $-3.699M $-1.475M $-18.785K $-1.482M $-2.857M $-1.485M

Five-Year Company Overview

Income Statement

Income Statement Income statement: Ainos is still essentially a pre-revenue company. Over the past few years it has not generated meaningful sales, while consistently recording operating losses and net losses. Earnings per share have been negative throughout, reflecting ongoing spending on development and operations without offsetting revenue. The trend shows a company still in the build-out phase rather than one with an established, profitable business model.

Balance Sheet

Balance Sheet Balance sheet: The balance sheet is very small, with limited assets and no meaningful cash cushion reported in the data. Equity is positive but modest, and a small amount of debt has appeared more recently. Overall, the company looks thinly capitalized and financially fragile, with little room to absorb large setbacks without additional funding. Its ability to scale likely depends on repeated access to external capital.

Cash Flow

Cash Flow Cash flow: Cash flows reflect the early-stage nature of the business. Operating cash flow has recently turned negative again, indicating that the company is spending more cash on its operations than it generates. Free cash flow is also negative, although capital spending appears light. This combination points to a reliance on financing activities—such as share issuance or other funding sources—to support ongoing development and commercialization efforts.

Competitive Edge

Competitive Edge Competitive position: Ainos’ main strength is in its intellectual property and data. It has built a sizable patent portfolio and a large proprietary scent database, which together create a meaningful barrier to entry in digital olfaction. The dual focus on AI-powered scent detection and novel therapeutics is unusual and gives the company multiple potential revenue streams, from industrial sensing to healthcare and veterinary uses. However, the commercial side is still early: customer traction is limited, revenue is not yet established, and the business depends heavily on a few key partnerships and proof-of-concept deployments. Larger, better-funded competitors in AI, sensors, and biotech could be tough rivals once the market opportunity becomes clearer.

Innovation and R&D

Innovation and R&D Innovation & R&D: Innovation is the clear centerpiece of Ainos. On one side, the AI Nose platform combines hardware sensors, a proprietary “smell language model,” and cloud software, backed by more than a decade of collected scent data. This creates a differentiated technology that can be applied to factories, healthcare diagnostics, and even robotics. On the other side, the VELDONA® platform aims to repurpose interferon therapy into a low-dose oral form for multiple human and animal diseases, with several clinical programs under way or planned. These efforts are science-heavy, highly experimental, and dependent on successful trials and regulatory approvals. The opportunity is significant if the technology works and gains adoption, but the scientific and execution risks are also substantial.

Summary

Summary: Ainos is a very early-stage, high-risk, high-uncertainty story. Financially, it is still pre-revenue with recurring losses, a very small balance sheet, and negative cash flow, implying ongoing dependence on external funding. Strategically, the company’s edge lies in its deep patent portfolio, proprietary scent data, and its dual-platform approach spanning AI-based sensing and novel therapeutics. If it can translate its innovations into reliable products, secure more partnerships, and move its drug pipeline through key clinical milestones, the business profile could improve meaningfully. Until then, the company remains in a development-heavy phase where execution, funding access, regulatory outcomes, and market adoption are all critical swing factors.

NEWS

November 13, 2025 · 4:15 PM UTC

Ainos Reports Third Quarter 2025 Financial Results

Read more

October 20, 2025 · 8:30 AM UTC

Water Tower Research Spotlights Ainos-NEXCOM Partnership as Catalyst for High-Growth Edge AI Expansion

Read more

October 14, 2025 · 8:30 AM UTC

Ainos and NEXCOM Partner to Expand AI Nose Ecosystem into Industrial Edge AI

Read more

October 7, 2025 · 8:30 AM UTC

Water Tower Research Highlights Ainos' Transition to Technology Company Following GICS Reclassification

Read more

October 2, 2025 · 8:30 AM UTC

Ainos Announces GICS Reclassification to Information Technology Sector

Read more